This is the authors' abstract. We don't add key points for this paper.
The development of a photosensitizer (PS) integrating real-time therapeutic monitoring capability represents a critical advancement in precision photodynamic therapy (PDT). Herein, three ruthenium(II)-triphenylamine photosensitizers (Ru1–3) were designed and synthesized. Detailed antitumor mechanism investigations revealed that Ru1 and Ru3 activated caspase-1, induced gasdermin D (GSDMD) cleavage and mitochondrial membrane potential (MMP) depolarization, and triggered cell pyroptosis. An increase in the luminescence intensity of Ru1 and Ru3 was observed during cell pyroptosis, indicating a significant augmentation of cytoplasmic viscosity during pyroptosis. Moreover, two-photon excitation experiments verified that they possessed photocytotoxicity in 3D multicellular tumor spheroids (MCTSs), and a similar luminescence amplification correlated with pyroptosis progression was observed. In vivo studies confirmed that Ru3 exhibits superior PDT efficacy and provides real-time feedback on treatment response via its self-reporting luminescence characteristics. This work provides new insights into the design and implementation of multifunctional photosensitizers for tumor cell pyroptosis with real-time therapeutic monitoring and two-photon imaging.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: